先看重点
在50名正在接受降压治疗的成年人中,为期8周的即时干预应用LowSalt4Life使点尿估算的钠排泄量下降462 mg,常规建议组的变化为381 mg(P=0.03),但血压差异无统计学意义(P=0.12)。试验样本很小,为开放标签,各指标结果也不一致。
证据类型
随机对照试验
解读依据
公开摘要
阅读重点
对照与不确定性
研究在问什么
钠摄入过多是重要的公共卫生问题,与高血压和心血管疾病风险升高相关。研究者检验了LowSalt4Life这款即时自适应手机应用,能否降低接受降压治疗的高血压成人的钠摄入。
研究了谁,如何研究
单中心、前瞻性、开放标签的随机对照试点试验。50名18岁及以上、正在接受高血压治疗的成年人按1:1随机(按性别分层)分入应用组(LowSalt4Life)或无应用组(常规饮食建议),为期8周。主要终点是用Kawasaki公式根据点尿估算的24小时尿钠排泄量的变化,采用非配对双侧t检验。次要结局包括食物频率问卷(FFQ)和24小时膳食回顾得到的钠摄入、24小时尿钠排泄量、血压,以及自评的坚持低钠饮食的信心。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1主要终点:应用组用Kawasaki公式估算的24小时尿钠排泄量下降462 mg(标准差1220),无应用组的变化为381 mg(标准差1460;摘要未标注正负号),P=0.03。
- 2另一项指标,即24小时尿钠排泄量的变化,应用组为-637 mg(标准差1524),无应用组为-322 mg(标准差1485),P=0.47,这一指标未显示出明确差异。
- 3应用组按24小时膳食回顾估算的钠摄入下降1537 mg(标准差2693),按FFQ下降1553 mg(标准差1764);无应用组分别下降233 mg(标准差2150)和515 mg(标准差1081);膳食回顾的P=0.07,FFQ的P=0.01。
- 4收缩压从基线到第8周在应用组变化-7.5 mm Hg,无应用组为-0.7 mm Hg(P=0.12);两组在坚持低钠饮食的信心上差异也不显著。
局限与不确定性
- 1仅50名参与者,属于试点研究,收缩压的差异(应用组-7.5 mm Hg,无应用组-0.7 mm Hg;P=0.12)估计不精确,样本太小,不足以回答血压问题。
- 2开放标签:参与者知道自己的分组,这可能影响FFQ、膳食回顾等自报摄入量的结果。
- 3各指标结果不一致:点尿估算和FFQ有显著差异,24小时尿钠排泄量和膳食回顾则无;摘要也未提及对多重检验的校正。
- 4主要终点是用公式根据点尿估算的值,而不是完整的24小时收集;仅8周、单中心,持久性和推广性未知。本文解读仅基于摘要。
对日常健康的启示
在这项小型试点中,提供及时低钠指导的应用在部分指标上降低了估算的钠摄入,但并非所有指标,血压差异也没有统计学意义。这只是早期线索,不能说明该应用能改善血压,也不能说明效果在8周之后仍会持续。正在接受高血压治疗的人,大幅调整饮食前应咨询临床医生。
如何联系自己的数据
钠摄入很难在家里准确测量,这项试验就是例子:尿液估算、FFQ和膳食回顾的结果并不一致。记录每餐钠含量的饮食日志或应用只能提供粗略参考,应以数周而不是数天的变化来判断。更直接的检查是家用血压计:每天固定时间测量,比较减盐前后的每周平均值。
如何理解这类证据
随机分组有助于因果推断,仍须检查分配、盲法、失访、随访时间和具体对照;标为随机试验不自动意味着高确定性。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
High dietary sodium intake is a significant public health problem in the United States. High sodium consumption is associated with high blood pressure and high risk of cardiovascular disease.
Objective
The aim of this study was to evaluate the effect of a just-in-time adaptive mobile app intervention, namely, LowSalt4Life, on reducing sodium intake in adults with hypertension.
Methods
In this study, 50 participants aged ≥18 years who were under treatment for hypertension were randomized (1:1, stratified by gender) into 2 groups, namely, the App group (LowSalt4Life intervention) and the No App group (usual dietary advice) in a single-center, prospective, open-label randomized controlled trial for 8 weeks. The primary endpoint was the change in the 24-hour urinary sodium excretion estimated from spot urine by using the Kawasaki equation, which was analyzed using unpaired two-sided t tests. Secondary outcomes included the change in the sodium intake measured by the food frequency questionnaire (FFQ), the 24-hour urinary sodium excretion, blood pressure levels, and the self-reported confidence in following a low-sodium diet.
Results
From baseline to week 8, there was a significant reduction in the Kawasaki-estimated 24-hour urinary sodium excretion calculated from spot urine in the App group compared to that in the No App group (-462 [SD 1220] mg vs 381 [SD 1460] mg, respectively; P=.03). The change in the 24-hour urinary sodium excretion was -637 (SD 1524) mg in the App group and -322 (SD 1485) mg in the No App group (P=.47). The changes in the estimated sodium intake as measured by 24-hour dietary recall and by FFQ in the App group were -1537 (SD 2693) mg and -1553 (SD 1764) mg while those in the No App group were -233 (SD 2150) mg and -515 (SD 1081) mg, respectively (P=.07 and P=.01, respectively). The systolic blood pressure change from baseline to week 8 in the App group was -7.5 mmHg while that in the No App group was -0.7 mmHg (P=.12), but the self-confidence in following a low-sodium diet was not significantly different between the 2 groups.
Conclusions
This study shows that a contextual just-in-time mobile app intervention resulted in a greater reduction in the dietary sodium intake in adults with hypertension than that in the control group over a 8-week period, as measured by the estimated 24-hour urinary sodium excretion from spot urine and FFQ. The intervention group did not show a significant difference from the control group in the self-confidence in following a low sodium diet and in the 24-hour urinary sodium excretion or dietary intake of sodium as measured by the 24-hour dietary recall. A larger clinical trial is warranted to further elucidate the effects of the LowSalt4Life intervention on sodium intake and blood pressure levels in adults with hypertension.
Trial registration
ClinicalTrials.gov NCT03099343; https://clinicaltrials.gov/ct2/show/NCT03099343.
International registered report identifier (irrid)
RR2-10.2196/11282.
来源与署名
Effects of a Novel Contextual Just-In-Time Mobile App Intervention (LowSalt4Life) on Sodium Intake in Adults With Hypertension: Pilot Randomized Controlled Trial.
Dorsch MP, Cornellier ML, Poggi AD, Bilgen F, Chen P, Wu C, An LC, Hummel SL.
JMIR mHealth and uHealth · 2020-08-10
DOI: 10.2196/16696 ↗PubMed · 32663139 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
昼夜活动节律紊乱与更高的死亡风险相关(109,365人)
在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。
Journal of the American Heart Association
五类运动都降低了静息血压,等长训练降幅最大
汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。
British Journal of Sports Medicine
盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降
在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。
The New England Journal of Medicine
智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤
在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。
The New England Journal of Medicine

